Panacell Biotech to Conduct Toxicity Tests for NK Cells, Exosomes, and Brown Adipose-Derived Stem Cells to Treat Patients with Long COVID

On August 10, 2022, Panacell Biotech Co., Ltd. said that natural killer (NK) cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness. Panacell Biotech is South Korea's research institute specializing in advanced regenerative medical cell therapy using adipose-derived stem cells (ADSC). The company announced on August 10,2022 that it will soon conduct those cells' and exosomes’ toxicity tests through clinical trials and laboratory animals.

Login Or Register To Read Full Story